ATRC AtriCure, Inc. - Common Stock

AtriCure has delivered a strong run over the past year, and the latest close at US$60.77 puts a clear spotlight on what investors are paying for its sales. The question now is how that recent performance lines up with the revenue the business is actually generating. The share price has gained 73.5% over the past year, which puts added weight on whether the current valuation can be explained by its sales base. The company’s focus on cardiac surgical devices means future growth in procedure...

AtriCure (ATRC) has drawn fresh attention after its shares closed at US$60.77, with recent returns over the past month and past 3 months sharply outpacing many healthcare peers. Recent trading has been strong for AtriCure, with a 30-day share price return of 24.84% and a 90-day share price return of 101.36%. This feeds into a year-to-date share price gain of 54.75% and a 1-year total shareholder return of 73.48%, even though the 5-year total shareholder return is down 12.62%. Spot fresh...

AXT Inc. (NASDAQ:AXTI) extended its winning streak to a fifth straight day on Monday, surging by as much as 16.4 percent in intraday trading to $81.50, as investors resumed buying positions amid its official membership in the S&P 600 index. Effective on the same day, the listed firm officially joined the S&P 600 index alongside […]

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Privitera executed the sale under a pre-established Rule 10b5-1 trading plan.

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials. Speaking at the Canaccord Genuity G

The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.

Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.

Inspire Medical Systems recently appointed AtriCure CEO Michael H. Carrel to its Board and committees, while long-serving director Casey M. Tansey plans to retire, as the company reported quarterly revenue of US$200.58 million and earnings of US$0.14 per share that exceeded analyst expectations despite a year-on-year decline. Alongside these governance changes, Inspire raised its full-year outlook and launched Project Horizon, aimed at unlocking US$30 million in annualized investment...

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

AtriCure (ATRC) drew fresh investor attention after filing two shelf registrations related to employee stock ownership offerings, covering up to 2,250,000 common shares and approximately US$78.8 million in potential issuance capacity. See our latest analysis for AtriCure. AtriCure’s recent shelf registrations arrive after a sharp swing in sentiment, with the stock posting a 42.47% 30 day share price return and a 16.40% 1 year total shareholder return, despite a weaker 3 year and 5 year total...

AtriCure, Inc. (NASDAQ:ATRC) has been delivering revenue growth and improved profitability, but the bigger question for investors is whether the latest results had any underlying catalysts strong enough to support the long-term growth potential. The company reported its Q2 FY26 earnings on July 23, delivering revenue of $153.6 million and an adjusted EPS of $0.18. […]

AtriCure Inc (ATRC) reports a 13% increase in revenue and a return to profitability, while navigating market challenges and setting optimistic guidance for the year.

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AtriCure (NASDAQ:ATRC) reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appendage management and open ablation franchises while noting continued pressure in minimally invasive

AtriCure (ATRC) delivered earnings and revenue surprises of +500.00% and +1.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?